Company intelligence / Profile preview
Synvista Therapeutics, Inc.
Montvale, New Jersey, United Statessynvista.com ↗
- Ownership
- Private
- Employees
- ~9
- Development stage
- Other
01
Overview
Synvista Therapeutics was a biotechnology company that developed diagnostic tests and drugs to identify and treat diabetic patients at high risk for cardiovascular disease. Their lead drug candidate, alagebrium chloride, was being developed for diastolic heart failure. The company also had a program to produce small molecule drugs that mimic the enzyme glutathione peroxidase (GPx), with ALT-2074 reaching Phase II clinical trials. All their drug candidates appear to have been discontinued.
- Therapeutic areas
- EndocrinologyCardiovascularMetabolic DisordersNephrology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Synvista Therapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Synvista Therapeutics, Inc..